EDUCATION > Educational Programs > E-Learning > Videos/Webcasts > 2012 Annual Meeting Webcasts > Advanced Prostate Cancer Video Panel > Understanding and Sequencing the Plethora of New Agents

Advanced Prostate Cancer 2012 Video Panel: Understanding and Sequencing the Plethora of New Agents

Activity Description

This educational activity will allow participants to develop an understanding of the four new FDA approved agents as well as the existing standard therapies for advanced prostate cancer. Particular attention will be devoted to sequencing of the new agents and positioning the use of the new agents compared to the older existing therapies.

Learning Objectives

After participating in this activity, participants should be able to:

  • diagnose castrate resistent prostate cancer (CRPC) and have a working knowledge of treatments and the proper order to administer treatments in the new era
  • manage CRPC with sipuleucel-T by learning the proper candidates for this treatment (asymptomatic or minimally symptomatic) and be able to counsel patients on the pros and cons of this therapy in the context of other new agents
  • acquire comprehension of how to treat CRPC patients with abiraterone and understand its use, side-effect profile and pros and cons of use
  • comprehend the use of docetaxel and cabazitaxel systemic chemotherapy agents in the context of the multi-disciplinary setting whereby urologists work with medical oncologists to jointly manage patients
  • aquire new knowledge to understand skeletal related events (SRE's) in advanced prostate cancer patients with bone metastases and learn to manage patients using zolondronic acid and/or denosumab

Faculty/Authors

Judd W. Moul, MD, FACS, Course Director
James H Semans MD Professor of Surgery
Duke University
Durham, NC
Disclosures: Astra Zeneca: Scientific Study or Trial ; Sanofi-Aventis: Health Publishing,Meeting Participant or Lecturer ; Dendreon: Consultant or Advisor,Meeting Participant or Lecturer ; Theralogix: Consultant or Advisor ; Ferring Pharmaceuticals Inc: Consultant or Advisor,Meeting Participant or Lecturer ; Amgen: Meeting Participant or Lecturer ; Medivation-Astellas: Consultant or Advisor ; Janssen- J and J: Consultant or Advisor,Meeting Participant or Lecturer

Daniel George, MD
Associate Professor of Medicine and Surgery
Duke University Medical Center
Durham, NC
Disclosures: Astellas Pharma US, Inc.: Consultant/Advisor; Bayer:
Consultant/Advisor; Dendreon Corporation: Consultant/Advisor, Investigator, Meeting Participant/Lecturer; Roche: Consultant/Advisor, Investigator, Meeting Participant/Lecturer; Ipsen Pharma: Consultant/Advisor, Investigator, Meeting Participant/Lecturer; Jansen: Consultant/Advisor, Investigator, Meeting Participant/Lecturer; Medivation, Inc.: Consultant/Advisor; Novartis Oncology: Consultant/Advisor, Investigator, Meeting Participant/Lecturer, Scientific Study/Trial; Pfizer Inc.: Consultant/Advisor, Investigator, Meeting Participant/Lecturer, Scientific Study/Trial; Sanofi Aventis Medical: Consultant/Advisor, Meeting Participant/Lecturer

J. Kellogg Parsons, MD, MHS
Associate Professor of Surgery
University of California, San Diego
La Jolla, CA
Disclosures: AMS: Meeting Participant or Lecturer

Acknowledgement for Support

Support provided by educational grants from the following companies:

AMGEN Astellas Janseen
Medivation Millennium

Clinical Trials, www.clinicaltrials.gov accessed 1/22/12.

Fizazi et al., ASCO 2010

Saad, et al. J Natl Cancer Inst 2004;96:879-82;

Fizazi, et al. J Clin Oncol 2010;28 (suppl 18) LBA4507.

Wolters Kluwer Pharma Solutions-2/5/12

Wolters Kluwer Source PHAST National Trends Integrated Monthly Audit accessed 2/5/12.

World Pharma News, 2010

Emerging Therapies for CRPC, Part 2: Sipuleucel-T, Cabazitaxel and Radium-223


Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110:1959-1966.

Clinicaltrials.gov identifier: NCT00699751.

D9902B Clinical Study Report; Biologics License Application: PROVENGE® (sipuleucel-T). September 2009. Seattle, WA: Dendreon Corporation.

De Bono et al, NEJM 2010

de Bono JS. et al. Lancet 2010 376: (9749): 1147-1154.

Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 2002;52:154-179.

Higano CS. In: Figg WD et al. Drug Management of Prostate Cancer. 2010:321. 2. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. V.4.2011.

Higano CS. Sipuleucel-T: autologous cellular immunotherapy for metastatic castration-resistant prostate cancer. In: Figg WD, Chau CH, Small EJ, eds. Drug Management of Prostate Cancer. New York, NY: Springer; 2010:321.

Kantoff PW et al. N Engl J Med. 2010;363:411-422.

Kantoff PW, Higano CS, Shore ND, et al; for the IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.

NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. V.4.2011. National Comprehensive Cancer Network Web site. www.nccn.org. Accessed October 10, 2011.

Nilsson. Lancet Oncol. 2007;8:587-594.

Parker C et al. ESMO 2011

Perez et al. Principles and Practice of Radiation Oncology. 5th ed. Lippincott Williams & Wilkins; 2007:103.

Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.

PROVENGE [package insert]. Dendreon Corporation; June 2011.

Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-1468.

Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009;27:5431-5438.

Tannock IF, de Wit R, Berry WR, et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.

Terris MK, Rhee A, Qureshi SM. Prostate cancer: metastatic and advanced disease. eMedicine Web site. http://emedicine.medscape.com/article/454114-print. Updated June 4, 2009. Accessed March 17, 2010.

Novel Agents for Androgen Deprivation Therapy


BJU Int. 2008 Dec;102(11):1531-8.

BJU International Volume 102, Issue 11
pages 1531-1538, 21 NOV 2008 DOI: 10.1111/j.1464-410X.2008.08183.x
http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2008.08183.x/full#f4

Eur Urol. 2009 Jun;55(6): 1488-9.

http://www.jnj.com/connect/news, accessed 3/9/12

J Clin Oncol 23, 8253, 2005

J Clin Oncol 30, 2012 (suppl 5; abstr LBA1)

J Clin Oncol 30, 2012 (suppl 5; abstr LBA1)

Journal of Clinical Oncology, S23:8253-8261

Lancet 2010 Apr 24;375(9724):1437-46

N Engl J Med. 2011 May 26;364(21):1995-2005

Taplin et al J Clin Oncol 30, 2012 (suppl; abstr 4521)

ADVERTISEMENT

ADVERTISEMENT
Donate
Contact
Press/Media
Sections
Term of Use
Site Map


ADVERTISEMENT